ライフサイエンスコーパス: false-negative

1 orted as being disease-free on FDG-PET ("PET false-negative").

2 rasound did not detect a retinal detachment (false-negative).

3 occasionally fall below the fixed threshold (false negatives).

4 lesions but missed 2 ICGA-confirmed lesions (false negatives).

5 tives) and missing the real expressed genes (false negatives).

6 T colonography and/or surgery (there were no false-negatives).

7 gative scans were true-negative, and 12 were false-negative.

8 tive scans for primary tumor were considered false-negative.

9 ringent, leading to a controllable number of false negatives.

10 full potential of chemical libraries due to false negatives.

11 n both pipelines resulting in a high rate of false negatives.

12 t sensitivity and minimize the likelihood of false negatives.

13 There were 18 false-negatives.

14 n loss, 15% for false-positives, and 33% for false-negatives.

15 However, false-negative (124)I PET/CT results as compared with po

16 False-negative (124)I PET/CT results as compared with po

17 100% sensitivity and 90% overall accuracy (0 false-negatives; 4 false-positives) in response predicti

18 crease in cases that were untested or tested false-negative (42.5% vs.8.9%) and so untreated.

19 nts with true-negative (658 g, P < 0.01) and false-negative (482 g, P < 0.01) results.

20 remaining 26 were as follows: 16 negative (9 false negative), 9 atypical, 1 indeterminate.

21 that snoReport 2.0 avoid false positives and false negatives, allowing to predict snoRNAs with high q

22 d in 9 of 20 FET cycles (45%), with only one false negative (among 54 transferred embryos).

23 t the malaria silver QCM could identify both false negative and misdiagnosis cases of routine microsc

24 ing agents, including those known to produce false negative and positive results.

25 f patients with solid malignancies; however, false negatives and false positives remain major limitat

26 positive predictive values with low rates of false negatives and false positives.

27 FDG-PET/CT resulted in no false negatives and fewer false positives than the other

28 ged by their intrinsic diversity, leading to false negatives and incomplete characterisation.

29 improved library still has library-specific false negatives and, for the first time, estimated the f

30 expected to be detectable within 1 s with 5% false-negative and 1% false-positive by administering th

31 me needed to detect a 0.1-mL remnant with 5% false-negative and 1% false-positive rates is less than

32 e/Epi test; Cepheid, Sunnyvale, CA) found no false-negative and 4 false-positive cobas Cdiff test res

33 To minimise false-negative and false-positive classifications, recom

34 Overall false-negative and false-positive fractions were 22% and

35 ge selectivity in cell recognition minimizes false-negative and false-positive results often associat

36 Validation Set 1 has 1 false-negative and Validation Set 2 has 1 false-positive

37 To explore reasons for false-negative and/or false-positive results, we used pf

38 high degree of fidelity and low rate of both false-negatives and false-positives in this approach.

39 diagnosed between surveillance assessments (false negatives) and two biopsied lesions were non-neopl

40 nd secondary hybridization) is less prone to false negatives, and the technique as a whole can potent

41 ted lower percentages of false positives and false negatives, and was able to report a higher number

42 e were 34 true-positive, 8 true-negative, 10 false-negative, and only 2 false-positive lesions for d-

43 The true-positive, false-positive, false-negative, and unconfirmed rates for unknown primar

44 To minimize false-negative BC results for patients already receiving

45 signal in the primary motor cortex (PMC), as false-negative blood oxygen level-dependent (BOLD) funct

46 lergological study is useful, could minimize false negatives, but should be considered as a complemen

47 site of interest is displaced; it mitigates false negatives by detecting a reporter compound that io

48 ts without evidence of CBD stones by EUS, no false-negative case was noted during the three-month fol

49 is, was significantly lower expressed in PET false-negative cases (5.3-fold change, P < .001) which p

50 ogic correlation although false-positive and false-negative cases exist.

51 212 cases from TMAs, and the overall rate of false-negative cases was 1.6% (16 of 978 cases).

52 g appropriate antimicrobial therapy, with no false-negative cases.

53 of in vitro results by identifying possible "false negatives." CITATION: Phillips MB, Leonard JA, Gru

54 fied as nonmelanocytic) and 252 (2.7%) being false negatives (clinically classified as nonmelanocytic

55 The resulting model decreases the rate of false negatives compared to EPA's screening approach.

56 artly responsible for the false positive and false negative compound identifications.

57 sequencing studies, we propose the Adaptive False-Negative Control (AFNC) procedure that can include

58 Nontriggered CT yielded false-negative CS in 8.8% of individuals and underestima

59 re often accompanied by unspecific symptoms, false-negative cultures or nonspecific low values of ser

60 correctly determined aggressive disease in 1 false negative cytology case and confirmed a negative cy

61 l misclassification was observed in terms of false negatives detected after the incorporation of infa

62 There were no false positive or false negative diagnoses.

63 in improved diagnostic confidence and lower false-negative diagnoses.

64 sify species-specific drug (Thalidomide) and false negative drug (D-penicillamine) in the conventiona

65 alls, but this does not ameliorate potential false negatives due in part to evaluating a limited pane

66 thogenic C. difficile strains, is limited by false negatives due to rapid toxin degradation.

67 ll have many false positive interactions and false negative edge loss due to the limitations of high-

68 lass analysis to estimate false positive and false negative error rates for each input method.

69 accurate measurements of false-positive and false-negative error rates.

70 In particular, the false negative errors restrict the search space of such

71 the user's tolerance for false positive and false negative errors; lowering the posterior probabilit

72 method that accounts for false-positive and false-negative errors to test deer saliva for chronic wa

73 Visual search experiments show that miss (false negative) errors are elevated when targets are rar

74 asily plagued by noise, false positives, and false negatives, especially with increasing levels of mu

75 (95% CI, 4.2 to 19.8), which included seven false-negative events in 69 patients with residual disea

76 e this using some notable false-positive and false-negative examples in MAPT and PRICKLE1 that can be

77 obe sequences, leading to false-positive and false-negative expression quantitative trait locus (QTL)

78 is Giemsa stained peripheral blood smear but false negative findings are always reported.

79 on-induced bias, reducing false positive and false negative findings.

80 imaging at 7 T of the breast eliminated all false-negative findings and reduced false-positive findi

81 al muscular dystrophies, and 21 patients had false-negative findings for DMD.

82 f parathyroid adenoma, whereas patients with false-negative findings had significantly smaller (mean

83 lcoxon rank sum tests, and true-negative and false-negative findings in CE-MARC groups were compared

84 s understressed patients who are at risk for false-negative findings on perfusion MR images.

85 icantly more common in CE-MARC patients with false-negative findings than with true-negative findings

86 False-negative findings were most commonly (37 [40%] of

87 initis lesions missed by the remote graders (false-negative findings) were more likely to be small (P

88 95% CI, 26.4%-33.3%), without any additional false-negative findings.

89 ere underpowered, which may have resulted in false-negative findings.

90 ollow-up analyses were performed to identify false-negative FIT results and interval CRCs.

91 and/or tumor characteristics associated with false negative (FN) AUS.

92 that were recorded as false positive (FP) or false negative (FN) compared to the reference method.

93 ion) and 78 were categorized as potential OC false-negative (FN) findings.

94 ovided by (18)F-FDG PET/CT will decrease the false-negative (FN) rate and thus improve the accuracy o

95 ion losses (FLs) and false-positive (FP) and false-negative (FN) response rates.

96 of the test reliability, as indicated by the false-negative (FN), false-positive (FP), and fixation l

97 Assess the impact of false-positives (FP), false-negatives (FN), fixation losses (FL), and test dur

98 ould be interpreted as a false positive or a false negative for cyanide exposure.

99 The results revealed false negatives for protein oligomer formation and false

100 been successfully validated with respect to false negatives for the sum PCB 28, 52, 101, 138, 153 an

101 Using IDF criteria, there were high false-negative fractions for both systolic and diastolic

102 R1, and an additional 51 patients (3.6%) had false-negative FS-R0 margins.

103 Four of the 6 false negatives had large subretinal hemorrhage (SRH) an

104 Eleven of these false-negatives had an associated hemothorax and 6 had p

105 The analysis focuses on the rate of false-negative HER2 tests, defined as IHC 0/1+ with an I

106 a analysis and to false-positive, as well as false-negative, hits.

107 Indeed, false positive and false negative HRMS detections are rare, albeit possible

108 vity with human and porcine fVIII leading to false-negative HSM results.

109 itive CTCAs were incorrectly reclassified as false-negative hybrid scans on the basis of (presumably)

110 ds generate high rates of false positive and false-negative identifications.

111 Odds ratio of obtaining a false negative in S1 (compared with S2) was 3.33.

112 n, the BVDV RT-PCR test had a higher rate of false negatives in all tissue types, especially for the

113 coreference resolution are a common cause of false negatives in information extraction from the scien

114 lation, with evidence of false positives and false negatives in the microarray data.

115 igh risk of misclassification, mostly due to false negatives in younger subjects.

116 (18)F-FDG PET/CT was false-negative in all cases with infected NV.

117 (68)Ga-DOTANOC and (68)Ga-DOTATATE were false-negative in only 1 of 18 patients.

118 e fetal CNV and that at least one of the two false negatives is due to a low fetal fraction.

119 losing analytes with low signal intensities (false negative) is comparatively low.

120 -seq and RNAcompete, usually suffer from the false negative issue.

121 I-RADS) version 2 score to better understand false-negative lesion characteristics.

122 had true-positive (18)F-FDG PET results but false-negative leukocyte scintigraphy results.

123 The success rate was 70%; false negatives mainly resulted from low intense peaks.

124 False-negative microvolt T wave alternans results were s

125 e led to both false-positive and potentially false-negative miRNA associations.

126 e a relevant number of patients with FDG-PET false-negative MM and a strong association between hexok

127 emographic differences between patients with false-negative MP MR imaging findings and those with cor

128 In humans, spatial patterns revealed false-negative observations and three malaria-positive d

129 Two-hundred thirty-three false-negative OFOQ results occurred in 80 of 287 seroco

130 ntiretroviral therapy was observed to have a false negative OMT result, from July 2015 urine samples

131 ed in LFA, provides a highly sensitive (zero false negatives on 50 hERG-sensitive drugs) and highly s

132 ken good care of, leading to either inflated false negatives or false positives.

133 rue-positive, false-positive, true-negative, false-negative, or equivocal findings.

134 eutic strategy based on what are essentially false-negative outcomes.

135 Most false-negative P. falciparum results were from samples w

136 ely false positive (misannotated enzyme) and false negative (pathway hole) reactions.

137 -positive, true-negative, false-positive and false-negative patients as classified against any refere

138 atment for suspected CDI cases may result in false-negative PCR results if there are delays in stool

139 False positive and false negative peaks detected from extracted ion chromat

140 In no case do we make a false negative prediction; for chlorine, bromine, boron,

141 rimentally confirmed, while 4 compounds were false negative predictions.

142 both the false discovery rate (FDR) and the false negative rate (FNR).

143 ients with residual axillary tumor activity (false negative rate 5/70 = 7%).

144 We estimated the false negative rate in the experiment by generating synt

145 This is consistent with a false positive and false negative rate of 0%.

146 for the first time, controlling the overall false negative rate of the screening algorithm to a desi

147 ia including mass error and isotope fit, the false negative rate typically accumulates upon advancing

148 failed to detect was <1%, implying that the false negative rate was extremely low.

149 all high performance while maintaining a low false negative rate, particularly, on "periplasm" and "e

150 re time-consuming and associated with a high false negative rate.

151 ent has a high identification rate and a low false negative rate.

152 dium are difficult to predict, having a high false negative rate.

153 ncertainty and variability and decreases the false negatives rate; hence, it may offer an improved sc

154 e opposite side of detection to minimize the false-negative rate (2.8% [1/35]).

155 mal SNB identification rate (IR) >/= 90% and false-negative rate (FNR) </= 10% were predetermined.

156 n and removal of clipped nodes, improves the false-negative rate (FNR) compared with SLND alone.

157 Oncology Group Z1071 trial reported a 12.6% false-negative rate (FNR) for sentinel lymph node (SLN)

158 rgeons Oncology Group Z1071 trial reported a false-negative rate (FNR) of 12.6% with sentinel lymph n

159 rate in SNP calling without sacrificing the false-negative rate although trimming is more commonly u

160 , our method reduces the average error rate, false-negative rate and false-positive rate by 26, 15 an

161 es were fit to the data, first assuming a 5% false-negative rate and subsequently allowing the asympt

162 important, and new approaches to reduce this false-negative rate are needed.

163 icates that the Xpert assay has an increased false-negative rate for detecting rifampin resistance wi

164 The false-negative rate for pure clustered microcalcificatio

165 False-positive rate and false-negative rate for small insertions and deletions d

166 the preprocessing methods did not affect the false-negative rate in SNP calling with statistical sign

167 inoma and a tumor-negative neck US, the high false-negative rate of (124)I PET/CT after recombinant h

168 1 of 27 cases; 95% CI: 62.1%, 93.5%), with a false-negative rate of 0%.

169 9 cases; 95% CI: 52.2%, 85.8%), again with a false-negative rate of 0%.

170 ation was 66.4% (95% CI, 62.8%-69.9%) with a false-negative rate of 2%.

171 d in the studied nodal basin for an in-basin false-negative rate of 4.0%.

172 ervical lymph node metastasis, thus giving a false-negative rate of 7.14%.

173 The higher analytic sensitivity and lower false-negative rate of HTS improves upon FC for MRD dete

174 As a result of the 30% false-negative rate of plasma genotyping, those with T79

175 Sensitivity and false-negative rate of the IRIS computer-based algorithm

176 The false-negative rate of the JCV serology in this study wa

177 ; specificity, 88.9% (95% CI: 88.8%, 88.9%); false-negative rate per 1000 screens, 0.8 (95% CI: 0.7,

178 The false-negative rate was 0% for all US findings and for a

179 The false-negative rate was 8.5% (3/35).

180 formed (PPV3), 30.4% (95% CI: 29.9%, 30.9%); false-negative rate, 4.8 per 1000 (95% CI: 4.6, 5.0); se

181 ing program had a high sensitivity and a low false-negative rate, suggesting that it may be an effect

182 or PET/CT particularly allows for a minimal false-negative rate.

183 e rate at the expense of a small increase in false-negative rate.

184 amSeq, which reduces both false positive and false negative rates by incorporating the pedigree infor

185 tives and, for the first time, estimated the false negative rates of CRISPR-KO screens, which are bet

186 False negative rates were also generally <5%; however, r

187 figures of merit, such as false positive and false negative rates, selectivity, specificity and effic

188 ch for stem-loop structures, leading to high false negative rates.

189 from drastically low sensitivities and high false negative rates.

190 se tools suffer from high false positive and false negative rates.

191 studies, and help reduce false positive and false negative rates.

192 to reduce the associated false positive and false negative rates.

193 ls are prone to both high false positive and false negative rates.

194 of prostate needle biopsies, which have high false negative rates.

195 this test has substantial false positive and false negative rates.

196 curacy and reduced false positive as well as false negative rates.

197 The lowest false-negative rates (5.5%-6.7%) were seen in studies th

198 n larger savings in memory at the expense of false-negative rates in addition to the false-positive r

199 93; 95% CI, 0.87 to 0.97; false-positive and false-negative rates of 22% and 0%, respectively, using

200 losses, <30% false-positive rates, and <30% false-negative rates) were recruited.

201 ecommendations; harms (false-positive rates, false-negative rates, surgery rates).

202 ver e-cigarette use), indicating substantial false-negative rates.

203 e, with an order of magnitude improvement of false-negatives rates over the state of the art, while k

204 l suffer from significant false-positive and false-negatives rates.

205 overlap between studies is primarily due to false negatives rather than false-positive gene identifi

206 There were no false-negative ratings.

207 asmodium falciparum hrp2 (pfhrp2) gene cause false-negative RDT results and have never been investiga

208 However, false-negative RDT results were identified and can under

209 False-negative RDT results with high parasitemia could b

210 the number of antimalarial treatments due to false-negative RDT results.

211 However, pfhrp2 gene deletions yielding false-negative RDTs, first reported in South America in

212 ed negative OFOQ results as true-negative or false-negative relative to nucleic acid amplification te

213 The absence of false negatives reported here opens up the possibility o

214 ect C. difficile contamination and result in false-negative reporting.

215 , and may explain an important proportion of false-negative resistance determinations.

216 ty indices (proportion of false-positive and false-negative responses, fixation losses, rho>0.31, P</

217 glucosinolates and growth, this is likely a false negative result caused by the limited population s

218 ctiae, there was a single false-positive and false-negative result each, for a sensitivity and specif

219 od of broth culture enrichment resulted in 1 false-negative result in 68 (1.5%).

220 If this test result is negative, a false-negative result of the mutation analysis should be

221 de-off between a false-positive result and a false-negative result.

222 2 lesions, with 10 false-positive and only 2 false-negative, resulting in a lesion-based detection ra

223 ble estimate of the 'true' TE by controlling false negative results associated with excessively high

224 identify diagnoses of non-DMD disorders and false negative results from 1975 to July 12, 2015.

225 rovides a mathematical approach to limit the false negative results occuring with the use of other no

226 eurysm can have a relapsing course providing false negative results of endoscopy and ultrasound if pe

227 ly contaminated sample evaluations showed no false negative results were generated from a variety of

228 roiliitis diagnoses (both false positive and false negative results).

229 assays, BiFC can produce false positive and false negative results.

230 e to catalyze the reverse direction to avoid false negative results.

231 Rates of false-negative results (1.0 to 1.5 per 1000 women) and r

232 Most of the patients with false-negative results (18/19) were classified as inacti

233 CI, 55.7%-63.0%), corresponding to 6 of 874 false-negative results (none met treatment criteria).

234 ing recurrent or persistent EMPD; causes for false-negative results according to their location, hist

235 ests, 68 (75.6%) were correct; there were 20 false-negative results and 2 false positives.

236 ities <100/muL, which accounted for 75.7% of false-negative results and 33.3% of PCR-detectable infec

237 by using MR imaging may thus help to reduce false-negative results and improve risk assessment.

238 equations to examine the association between false-negative results and participant, clinical, and te

239 Rates of false-positive and false-negative results and recommendations for additiona

240 tify late-onset Pompe disease often leads to false-negative results and subsequent delays in identifi

241 l mammography may receive false-positive and false-negative results and subsequent imaging and biopsi

242 tes that PFGE is prone to false-positive and false-negative results and suggests the need for a new g

243 These programs will need to be aware that false-negative results are a possibility.

244 Rates of false-negative results are low.

245 is essential for preventing the reporting of false-negative results due to the high-dose "hook" effec

246 ed to an overestimation of response (yielded false-negative results for residual disease) in 66.7% (1

247 sitive results in 26% (five of 19 patients), false-negative results in 11% (two of 19 patients) and b

248 ottest sentinel lymph node would have led to false-negative results in 19 of 475 (4%) of all patients

249 The criteria resulted in false-negative results in 8 (1.9%) patients, 6 of whom w

250 test performance and factors contributing to false-negative results in longitudinal studies, we exami

251 PET/CT provided false-positive and false-negative results in six and three patients (PPV, 8

252 However, the risk of PET false-negative results in the presence of carbidopa is a

253 d likelihood of empirical therapy leading to false-negative results in these patients.

254 cN1 breast cancer is unclear because of high false-negative results reported in previous studies.

255 er of true- and false-positive and true- and false-negative results were extracted to fit a cross-tab

256 False-negative results were found in 2 patients and occu

257 No false-negative results were found.

258 ults exhibited low temporal variability, (b) false-negative results were not obtained, (c) the indoor

259 g four marker peptides, no false-positive or false-negative results were obtained.

260 Two false-negative results were related to poorly differenti

261 vel parasitemia, and PfHRP-II tests can give false-negative results when P. falciparum strains do not

262 ml (11.8%), there were larger proportions of false-negative results with 1.0 ml (29.4%; P = 0.2) and

263 There were 49 cases of RDT false-negative results with a parasite density range of

264 Seven of the 1982 patients (0.4%) had false-negative results with the staged algorithm.

265 The AST systems showed false-negative results with varying numbers, misidentify

266 62 (52.1%) had nonosteoporotic T-scores (DXA false-negative results), and most (97%) had L1 or mean T

267 ters (including the clinical implications of false-negative results), the exclusion of transmission e

268 problems associated with false-positive and false-negative results, inconsistencies and low reactivi

269 resulting in increases in false-positive and false-negative results.

270 es result in weak antibody binding and cause false-negative results.

271 dies, potentially causing false-positive and false-negative results.

272 removed from the transfer inoculum to avoid false-negative results.

273 e clinical potential but give high levels of false-negative results.

274 low quantities because of the high number of false-negative results.

275 ignancies but can lead to false-positive and false-negative results.

276 0 false-positive results, and 44 (73%) had 0 false-negative results.

277 hatase levels were independent predictors of false-negative results.

278 ex, and HIV subtype were not associated with false-negative results.

279 The overall rate of false-negative samples was 0.84% (six of 711 samples).

280 specificity and gave 3 false-positive and 4 false-negative scans.

281 egative; there were 14 false-positive and 29 false-negative scans.

282 The observed false-negative screening results also underline that BM

283 ogenicity, host factors, vaginal microbiome, false-negative screening, and/or changes in antibiotic r

284 nt had better control of false positives and false negatives (sensitivity = 0.89, specificity = 0.91,

285 False positive and false negative signals are difficult to distinguish, whi

286 The one false-negative specimen was from a patient with a pseudo

287 /16 (81.3%) false-positive specimens and 1/2 false-negative specimens, resulting in a final sensitivi

288 positive cases were PET-negative, whereas 10 false-negative SPECT cases were identified using PET.

289 True-positive (38% vs. 37.2%, P = 0.505) and false-negative studies (6.5% vs. 7%, P = 0.450) were not

290 aining at least one screen-detected mass, 17 false-negative studies, 20 false-positive studies, and 1

291 All 4 false-negative stx1 or stx2 results were reported for fr

292 form better (in terms of false positives and false negatives) than the vendor-supplied software packa

293 Although ligand enrichment was high, the false negatives, the false positives, and the inability

294 ttenuating the number of false positives and false negatives under high-throughput screening conditio

295 analysis using FamSeq reduced the number of false negative variants by 14-33% as assessed by HapMap

296 The rate of false negatives varied among the calves.

297 ive strains, and statistical corrections for false negatives, we find that indel rates increase by 10

298 for global asymmetry, and hence suffer from false negatives when asymmetry is localised to part of a

299 smaller in a blood spot, there is a risk of false negatives with DBS.

300 False-negative Xpert results (adjusted odds ratio [aOR],